Breast Milk Feeding for Neonatal Gastrointestinal Complications
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial compares two feeding methods to assess their impact on feeding success and gut health in infants with certain intestinal conditions. One group will receive only human milk (Exclusive Human Milk), while the other will follow current standard feeding practices (Standard of Care), which may include formula. The trial seeks infants with specific intestinal issues, such as gastroschisis or intestinal atresia, who have not yet started feeding. This unphased trial offers a unique opportunity to contribute to understanding the best feeding practices for infants with these conditions.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that human milk is highly recommended for feeding both premature and full-term babies, often regarded as the healthiest choice. Studies have found that exclusive human milk feeding can lead to better health outcomes, such as a lower risk of movement problems in early childhood, particularly for those born very early. Human milk also aids in developing healthy gut bacteria, crucial for digestion and overall health.
Regarding safety, babies generally tolerate human milk well. No major negative effects have been reported for those fed exclusively with human milk, making it a safe option for newborns. Consequently, many hospitals use donor human milk when a mother's own milk is unavailable.
Overall, exclusive human milk feeding is not only safe but also supports healthier growth and development.12345Why are researchers excited about this trial?
Researchers are excited about the potential of exclusive human milk feeding for addressing neonatal gastrointestinal complications. Unlike the standard care options, which often involve formula feeding and limited use of donor human milk (DHM), this approach emphasizes the benefits of human milk as the primary nutritional source. Human milk is rich in bioactive compounds that can promote gut health and development, potentially reducing the risk of complications like necrotizing enterocolitis. The study aims to explore how exclusive human milk feeding might offer superior outcomes for infants, especially those requiring surgical interventions, by leveraging the natural properties of human milk to improve recovery and growth.
What evidence suggests that this trial's treatments could be effective for neonatal gastrointestinal complications?
This trial will compare the effects of exclusive human milk feeding with standard care for neonatal gastrointestinal complications. Research has shown that feeding babies only human milk can improve feeding and gut health. Studies have found that preterm babies who receive human milk, either from their mothers or donors, usually tolerate feeding better. Additionally, a diet of only human milk is linked to a lower risk of death in babies with certain intestinal issues. The gut bacteria of babies fed with mother's milk or donor milk also benefit, which is important for overall health. These findings suggest that feeding only human milk might be beneficial for babies with digestive problems.12367
Who Is on the Research Team?
Katie Strobel, MD
Principal Investigator
Seattle Children's Hospital
Are You a Good Fit for This Trial?
This trial is for infants with specific intestinal conditions like gastroschisis, omphalocele, and Hirschsprung's disease. It's not open to those who've started feeding, are under 34 weeks gestation, or have complications that prevent milk tolerance.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Infants receive either an exclusive human milk diet or standard feeding practices to assess feeding outcomes and gut microbiome changes
Follow-up
Participants are monitored for safety and effectiveness after treatment, including central line infection rates and gut microbiome analysis
What Are the Treatments Tested in This Trial?
Interventions
- Exclusive Human Milk
- Standard of Care
Trial Overview
The study compares the effects of an exclusive human milk diet against standard feeding on the gut microbiome and how quickly infants with congenital gastrointestinal issues can tolerate full feeds.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Mothers will consent to providing DHM (if qualifies per hospital policy) or formula if MOM is not available. Infants are only eligible to receive donor milk only if 1) MOM is not available 2) if infant initiates feeds before day 3 of age. The donor milk feed would be stopped on day 5 of age. After day five of age, the infant will receive formula if MOM is not available. This is congruent with the current donor milk policy (see Policy #12785). It is highly unlikely given these infants would receive any donor milk because these infants require surgery and often are waiting return of bowel function . The median age of initiation of feeds is 12 days of age for infants with gastroschisis (PMID: 33647253) which exceeds the days of what the hospital policy says for eligibility which is initiates feed before day 3 of age. If the infant does not qualify for any donor milk and MOM is not available, the infant will receive formula
Mothers will consent to providing DHM if MOM is not available. If the infant reaches 100 ml/kg/day of feeds (one feed advancement prior to full feeds) and MOM remains unavailable, they will transition to formula in preparation for discharge. Infants cannot be discharged on donor milk.
Exclusive Human Milk is already approved in United States, European Union for the following indications:
- Nutrition for infants 0-6 months
- Support for gut health in neonates with congenital gastrointestinal pathologies
- Nutrition for infants 0-6 months
- Support for gut health in neonates with congenital gastrointestinal pathologies
Find a Clinic Near You
Who Is Running the Clinical Trial?
Seattle Children's Hospital
Lead Sponsor
Published Research Related to This Trial
Citations
Breast Milk Feeding for Neonatal Gastrointestinal ...
This study explores the use of an exclusive human milk diet versus standard feeding practices to compare the influence on feeding outcomes and the gut bacteria ...
Unlocking the Potential: A Systematic Literature Review on ...
Preterm infants who receive human milk, whether from their biological mothers or through donors, may experience improved feeding tolerance ...
Exclusive human milk for infants with gastroschisis
Exclusive human milk was associated with a reduced risk of mortality (RR = 0.38, 95% CI: 0.15โ0.99, I2 = 0%). There were no statistically ...
Outcomes in very preterm infants receiving an exclusive ...
This study compared unfortified pasteurised human donor milk and formula supplements. The principal outcome was survival to 34w postmenstrual age without ...
Impact of mother's own milk vs. donor human milk on gut ...
This systematic review focuses on the effects of predominant DHM vs. MOM feeding on the gut microbiota composition in preterm infants.
Comparing early life nutritional sources and human milk ...
Many studies have consistently shown that human milk feeding (i.e. breastfeeding) is the strongest predictor of gut microbiota composition in ...
Exclusive human milk diet is associated with lower risk of ...
An EHMD is associated with a decrease in the odds of early childhood motor function impairment among infants born before 32 weeks of gestation.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.